Abcam sees first-half revenues up 13.5%

AIM-listed bioscience firm Abcam is on track to meet profit forecasts for the full-year after first-half revenues rose by 13.5% in the six months to December 2011.

AIM-listed bioscience firm Abcam is on track to meet profit forecasts for the full-year after first-half revenues rose by 13.5% in the six months to December 2011.

The protein research tools supplier said that the business is performing well, "driven by our strategy of providing a broadening range of high quality products and support to the global protein research community."

Subscribe to MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free
https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Sign up
MoneyWeek

MoneyWeek is written by a team of experienced and award-winning journalists, plus expert columnists. As well as daily digital news and features, MoneyWeek also publishes a weekly magazine, covering investing and personal finance. From share tips, pensions, gold to practical investment tips - we provide a round-up to help you make money and keep it.